Summary
Signal counts
Assets tracked: 4
Watchlist assets: 3
Registry stop assets: 3
Sponsor overview
Washington University School of Medicine
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03655444 | https://clinicaltrials.gov/study/NCT02669914 | https://clinicaltrials.gov/study/NCT06445166 | https://clinicaltrials.gov/study/NCT01988831 | https://clinicaltrials.gov/study/NCT07662031
Assets
Linked programs
- Abemaciclib: Registry Stop Signal (4/5)
- MEDI4736: Registry Stop Signal (4/5)
- Propranolol Hydrochloride: Registry Stop Signal (4/5)
- Tovecimig: Low Signal (0/5)